Singapore becomes the first country to approve OPTIM.AI™, KYAN’s Personalized Medicine Solution for cancer patientsMay 01, 2023
Poster on clinical evaluation of combination-specific sub-population T-cell lymphoma presented at AACR 2023 Annual MeetingApril 01, 2023
Target prioritization and identification of novel nucleic acid therapies against MYC-driven HCC published in Bioengineering & Translational MedicineSeptember 01, 2022
Rational drug design using KYAN’s ex vivo platform for liver cancer published in Journal of Experimental & Clinical Cancer ResearchAugust 01, 2022
Prospective clinical data on KYAN’s dose modulation platform presented at the ASCO 2022 Annual MeetingJune 01, 2022
KYAN Therapeutics and Curie Oncology Announce Collaboration to Provide Personalized Cancer TestMay 01, 2022
KYAN Therapeutics and Aesculape CRO Partner to Offer Drug Development Biopharma ServicesApril 01, 2022
Clinical Data on KYAN’s personalized oncology platform presented at the 2021 ASH Annual MeetingNovember 01, 2021
Data on Novel HDACi Targeting KRAS-mutated Cancers presented at the AACR-KCA Joint Conference on Functional Precision Medicine in Solid TumorsNovember 01, 2021
